Shobhit Dhawan is managing director of Ligase BioPartners. Previously he managed Oncode Oncology Bridge Fund I, where he built and financed early-stage therapeutic and platform companies emerging from the Oncode Institute. Prior to Oncode, he was Investment Manager at Amsterdam Academic Ventures, focusing on company creation and early financings across life sciences and technology.

Shobhit holds a Ph.D. in Immunology from the University of Amsterdam and serves on the Board of Directors of sCellgen, 51x Therapeutics and Simmunext Biotherapeutics.